TACRODRUGS

STREPTOMYCES-BASED CELL FACTORIES FOR THE PRODUCTION OF TACROLOGUES DRUGS
Project acronym: TACRODRUGS

Consortium
- Marta Mendes, IBMC - Instituto de Biologia Molecular e Celular, Portugal
- Jesús F. Aparicio, Universidad de León, Spain
- Harald Gross, University of Tuebingen, Germany
- Felix Hausch, Max Planck Institute of Psychiatry, Germany
- Antonio Rodríguez García, Asociación de Investigación Inbiotec Instituto de Biotecnología de León, Spain
- Håvard Sletta, SINTEF Matarials and Chemistry, Norway
- Wolfgang Wohlleben, Eberhard-Karls-Universitaet Tuebingen, Germany

In the last decade significant efforts have been made in the development of “universal” hosts for the expression of natural products derived from bacterial specialized metabolism. This approach has originated promising results regarding the identification of novel bioactive compounds. However, the production yields are low unveiling a deficient metabolic flux background and undermining this strategy for downstream industrial applications that rely on high production yields. TACRODRUGS introduces the concept of a “specialized” expression host that combines the stability features of the universal expression host with the metabolic fitness for producing high added-value products.

The main goal of TACRODRUGS is to develop a sustainable and robust microbial industrial platform for the production of tacrolimus and non-immunosuppressive tacrolimus analogues (tacrologues) through the synergic use of synthetic biology principles and metabolic engineering methodologies, guided by global metabolic network understanding.